$2.5 Million Prospectus SaleEmerald Health Therapeutics Announces $2.5 Million Prospectus Sale and Concurrent Secondary Sale V.EMH | 26 minutes ago NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the Investor) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,385,965 units of Emerald (each, a "Unit") at a price of $0.57 per Unit for total gross proceeds of $2,500,000 (the "Offering"). Each Unit will consist of one common share of Emerald (each, a "Common Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the Investor to acquire one common share of Emerald (each, a "Warrant Share") at a price of $0.75 per Warrant Share for a period of five years following the closing of the Offering. In the event that the closing sale price of the Common Shares on the TSX Venture Exchange, or such other principal exchange on which the Common Shares are then trading, is greater than $1.50 per Share for a period of ten consecutive trading days at any time after the closing of the Offering, Emerald may accelerate the expiry date of the Warrants by giving written notice to the Investor and in such case the Warrants will expire on the 15th day after the date on which such notice is given by Emerald. The Investor has also agreed to purchase from Emerald Health Sciences Inc. ("Sciences"), a control person of Emerald, 4,385,965 common shares of Emerald (each, a "Secondary Share") at a price of $0.57 per Secondary Share (the "Secondary Sale"). The Company intends to use the net proceeds of the Offering for general working capital purposes. The Company will not receive any proceeds from the Secondary Sale. The Treasury Shares and the Secondary Shares will be offered by way of a shelf prospectus supplement to be filed in all of the provinces of Canada pursuant to National Instrument 44-102 Shelf Distributions. The closing date of the Offering and the Secondary Sale is scheduled to be on or about November 20, 2019 and is subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and applicable securities regulatory authorities. This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.